Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Boehringer Ingelheim
Biotech
PureTech's deupirfenidone shows durable effect in IPF study
PureTech presented results of an open-label extension study of itsidiopathic pulmonary fibrosis candidate deupirfenidone, showing its durability.
Kevin Dunleavy
May 20, 2025 5:15pm
Boehringer's phase 3 lung data get muted response from analysts
May 19, 2025 9:24am
Boehringer flexes staying power of HER2-mutant lung cancer med
Apr 28, 2025 9:00am
Boehringer slots synthetic lethal program into oncology pipeline
Apr 23, 2025 7:45am
Boehringer lines up B-cell depletion autoimmune R&D via Cue deal
Apr 15, 2025 4:45am
German program matches lost NIH grants with pharma funders
Apr 7, 2025 10:50am
